Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nearly 25% of U.S. Adults Take an Obesogenic Prescription Drug

Key clinical point: Clinicians should try to minimize use of obesogenic drugs and focus on prescribing agents that are weight neutral or that trigger weight loss.

Major finding: During 2013-2016, 23% of U.S. adults had used at least one obesogenic prescription drug during the previous 30 days.

Study details: NHANES, a survey of a representative sample of U.S. residents during 2013-2016.

Disclosures: NHANES is run by the U.S. Centers for Disease Control and Prevention and receives no commercial funding. The authors reported no conflicts of interest.


Hales CM et al. Obesity Week 2019, Abstract T-OR-2037.